Quantity of eligible patients: CDEC discussed the uncertainty in the number of sufferers with reasonably severe to serious hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some clients who're categorised as owning delicate or reasonable condition might have a serious bleedi